Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The INO news feed on Stock Titan aggregates company-issued press releases, regulatory updates, and other market-moving disclosures so readers can follow how INOVIO’s DNA medicine programs progress over time.
A major focus of recent INOVIO news is INO-3107, an investigational DNA medicine for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract. Updates include completion of a rolling Biologics License Application (BLA), FDA acceptance of the BLA for review under a Standard classification, and discussion of the accelerated approval pathway. News items also highlight clinical data showing reductions in the number of surgeries required by trial participants and long-term durability results from retrospective analyses.
Investors can also find announcements on capital-raising transactions, such as underwritten public offerings of common stock and warrants disclosed in Form 8-K filings and related press releases. INOVIO frequently reports on financial results, including quarterly earnings releases, as well as corporate governance and compensation matters like inducement stock option grants under its Inducement Plan.
Additional coverage includes scientific and clinical milestones, such as publication of Phase 1 proof-of-concept data for DNA-Encoded Monoclonal Antibody (DMAb) technology in Nature Medicine and preclinical progress in DNA-encoded protein (DPROT) programs. Conference participation and investor events are also regular topics. For followers of INO stock, this news page offers a centralized view of the company’s clinical, regulatory, financial, and strategic communications.
INOVIO has appointed Jacqueline Shea, Ph.D., as President and CEO, effective immediately. Dr. Shea, who joined INOVIO in March 2019 as COO, will succeed Dr. J. Joseph Kim, who has resigned from the board. Dr. Shea possesses over 25 years of leadership experience in biotech, including roles at Aeras and Emergent BioSolutions. The board looks forward to her leadership during challenging times and plans to appoint her as a director post the annual stockholders' meeting on May 16, 2022. Dr. Shea aims to advance INOVIO's DNA medicines technology, improving global patient health.
INOVIO (NASDAQ: INO) will release its first quarter 2022 financial results after market close on May 10, 2022. A live conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The company continues to focus on DNA medicines for infectious diseases, cancer, and HPV-related conditions, with candidates VGX-3100 and INO-4800 undergoing evaluation in Phase 3 trials. For more information, visit www.inovio.com.
Geneos Therapeutics announced a successful $17 million Series A2 financing led by Flerie Invest, enhancing its clinical trial for advanced hepatocellular carcinoma (HCC). The funding will expand the GT-30 Phase Ib/IIa trial from 24 to 36 patients, utilizing the personalized cancer vaccine GNOS-PV02 combined with a DNA-encoded cytokine and PD-1 checkpoint inhibitor. Dr. Ted Fjällman joins the Board, bringing European investor expertise. The company reported tumor reduction in over half of the initial patients treated and aims to release further efficacy data in 2022.
INOVIO (NASDAQ: INO) announced that CEO Dr. Joseph Kim will participate in a fireside chat and 1x1 meetings at Oppenheimer's 32nd Annual Healthcare Conference on March 15, 2021, at 8:00 AM ET. The event will focus on the company's work in developing DNA medicines for infectious diseases and cancer treatments, including Phase 3 trials for VGX-3100 and INO-4800, a COVID-19 vaccine. A webcast of the presentation can be accessed via the INOVIO Investor Relations page.
INOVIO (NASDAQ: INO) reported financial results for Q4 and year-end 2021, with total revenue of $839,000 and $1.8 million respectively, down from $5.6 million and $7.4 million in 2020. The net loss widened to $106.9 million, or $0.50 per share, compared to a net loss of $24.3 million the previous year. Key developments include ongoing clinical trials for COVID-19 vaccine INO-4800, with plans to amend its Phase 3 trial endpoint to focus on severe disease. Other advancements include completed enrollments for various therapeutic programs, highlighting INOVIO's commitment to combating infectious diseases and cancer.
INOVIO (NASDAQ: INO) will announce its fourth quarter 2021 financial results after market close on March 1, 2022. A live conference call is scheduled for 4:30 p.m. ET to discuss these results and provide a general business update. INOVIO focuses on DNA medicines targeting infectious diseases and cancers, currently evaluating VGX-3100 for cervical dysplasia and INO-4800 as a COVID-19 vaccine in Phase 3 trials. Investors can access the call and archived audio on their website.
INOVIO (NASDAQ: INO) announced key updates on the Phase 3 program for VGX-3100, an immunotherapy targeting HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL). The second global trial, REVEAL2, has completed enrollment, with top-line results expected in 2H22. REVEAL1's follow-up showed a favorable safety profile and continued efficacy at 88 weeks. Additionally, the first participant has been dosed in a separate Phase 3 trial in China, and INOVIO is collaborating with QIAGEN to develop a pre-treatment biomarker to enhance clinical outcomes.
INOVIO (NASDAQ: INO) announced its rapid evaluation of COVID-19 DNA vaccines INO-4800 and INO-4802 against the Omicron variant (B.1.1.529). The company has initiated pre-clinical development of an Omicron-specific DNA vaccine. INO-4800 has shown T cell responses, suggesting resilience against variant mutations, with data expected soon. Dr. Joseph Kim emphasized INO-4800's strong immune response, citing its potential against current and future variants. The vaccine's stability at room temperature supports its global deployment.
INOVIO (NASDAQ: INO) has initiated a Phase 1b clinical trial for its Ebola vaccine candidate, INO-4201, with several volunteers already dosed. The study assesses INO-4201 as a potential booster for individuals previously vaccinated with Ervebo. Preclinical results indicated strong tolerability and 100% seroconversion after two doses. The trial will involve around 50 participants, evaluating safety and immunogenicity. Notably, INO-4201 offers advantages in stability and storage, essential for use in tropical environments.
INOVIO (NASDAQ:INO) announced it will give eight presentations at the 34th International Papillomavirus Conference from November 15-19, 2021. Key topics include updates from the VGX-3100 clinical trials, which are in Phase 3 for cervical high-grade lesions and Phase 2 for anal and vulvar HSIL. Additionally, the study on INO-3107 for recurrent respiratory papillomatosis will be shared. Collaborations with Optum Life Sciences will present data on the epidemiology and treatment effectiveness for HSIL in the U.S. This event highlights INOVIO's ongoing commitment to HPV-related diseases and immune response development.